Gilead shot prevents all HIV cases in trial

Original Article ↗ Hacker News Discussion ↗

Trial design, ethics, and results

  • PURPOSE 1 is a Phase 3, double‑blind, randomized PrEP trial in ~5,300 cis women/adolescent girls (16–25) across South Africa and Uganda.
  • Participants were randomized 2:2:1 to:
    • Twice‑yearly subcutaneous lenacapavir
    • Daily oral Descovy
    • Daily oral Truvada
  • Because effective PrEP already exists, a placebo/no‑PrEP arm was considered unethical. Background HIV incidence (“bHIV”) and Truvada served as comparators.
  • Reported outcomes: 0 HIV infections among 2,134 on lenacapavir vs 16 among 1,068 on Truvada; lenacapavir superior to both bHIV and Truvada with very low incidence and p<0.0001.
  • Participants were already sexually active, instructed to live as usual, and not deliberately exposed to HIV. High local prevalence makes incident infections statistically expected in controls.

Mechanism, dosing, and adherence

  • Lenacapavir is a capsid inhibitor used in HIV treatment; here it’s used as long‑acting PrEP.
  • Commenters stress this is not a vaccine but prophylactic antiviral therapy, analogous to existing oral PrEP but with much longer dosing intervals (every 6 months vs daily).
  • Large adherence benefits are anticipated: easier for people who struggle with daily pills, face stigma, have controlling partners, or costly clinic access.
  • Questions raised about how rigid the 6‑month schedule must be (e.g., 7 months) and what happens if someone stops after having had subclinical infections; this remains unclear in the discussion.

Safety, cost, and access

  • One commenter links to side‑effect listings, suggesting tolerability in healthy people needs scrutiny, especially for mass prophylaxis.
  • Others note it will likely be expensive under patent and only become broadly cheap after expiry, unless subsidized programs intervene.
  • There is significant concern about equity: Africa as a historical site of unethical trials, IP barriers, and whether high‑risk populations in poorer countries will actually get the drug.

Social and behavioral dimensions

  • Several posts emphasize social context: gender‑based violence, rape, and power imbalances in relationships driving women’s HIV risk.
  • Some women reportedly use PrEP secretly to protect themselves without provoking accusations of infidelity.
  • Parallel debates on condoms vs PrEP highlight that multiple overlapping methods are valuable; adherence, pleasure, and real‑world behavior all matter.

Broader reflections

  • Many commenters express excitement that this could be a major step toward controlling or even eventually eradicating HIV, if scaled globally.
  • Others temper this with skepticism about pharma behavior, trial framing (100% efficacy claims), and broader distrust fueled by past corporate and public‑health failures.